Literature DB >> 16601875

Psychological complications of patients with Gaucher disease.

W Packman1, T Wilson Crosbie, A Riesner, C Fairley, S Packman.   

Abstract

The Minnesota Multiphasic Personality Inventory (MMPI-2) is commonly used in chronic illness and chronic pain populations to assess psychological functioning. We report the results of the first study employing the MMPI-2 to assess psychological aspects of patients with Gaucher disease, type I (GD) is an inborn error of metabolism with unique features as a chronic illness: the disorder often presents with mild symptoms, and is frequently diagnosed in later childhood or adulthood; the treatment is highly efficacious, but, that same treatment is intrusive and expensive and requires that patients restructure their work and personal schedules. In this study, 28 patients with GD completed the MMPI-2 and a background questionnaire. GD patients scored significantly higher than the MMPI-2 normative sample on MMPI-2 scales of Validity (K), Hypochondriasis (Hs), Depression (D), Hysteria (Hy), Psychasthenia (Pt) and Schizophrenia (Sc). Individuals with elevated scores on the Hs, D and Hy scales tend to have somatic concerns and depressed mood. Under stress, they are likely to report physical symptoms. Elevated Pt and Sc scales suggest psychological turmoil and, possibly feelings of isolation. An elevated K scale indicates a tendency for individuals to deny psychopathology. The length of time the patient with GD had been on enzyme replacement therapy was not significantly related to any of the 13 MMPI-2 scales. Cohorts of patients with chronic heart disease (CRHD) and cohorts of patients with chronic pain were utilized as comparative populations in this investigation. The elevated scores of the GD patients on MMPI-2 scales Hs, D and Hy were similar to those of the CRHD population. The chronic pain patients also showed elevations on MMPI-2 scales Hs, D and Hy, which were elevated in the GD patients; the elevations in the chronic pain patients were higher than those shown by the GD patients. We conclude that patients with GD exhibit moderate to severe psychological complications, similar to patients with other long-term chronic illnesses.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16601875     DOI: 10.1007/s10545-006-0154-x

Source DB:  PubMed          Journal:  J Inherit Metab Dis        ISSN: 0141-8955            Impact factor:   4.982


  15 in total

1.  Quality of life assessment in adults with type 1 Gaucher disease.

Authors:  B J Masek; K B Sims; C M Bove; M S Korson; P Short; D K Norman
Journal:  Qual Life Res       Date:  1999-05       Impact factor: 4.147

2.  METABOLISM OF GLUCOCEREBROSIDES. II. EVIDENCE OF AN ENZYMATIC DEFICIENCY IN GAUCHER'S DISEASE.

Authors:  R O BRADY; J N KANFER; D SHAPIRO
Journal:  Biochem Biophys Res Commun       Date:  1965-01-18       Impact factor: 3.575

3.  The health-related quality of life of adults with Gaucher's disease receiving enzyme replacement therapy: results from a retrospective study.

Authors:  A M Damiano; G M Pastores; J E Ware
Journal:  Qual Life Res       Date:  1998-07       Impact factor: 4.147

Review 4.  Enzyme therapy for Gaucher disease: the first 5 years.

Authors:  G A Grabowski; N Leslie; R Wenstrup
Journal:  Blood Rev       Date:  1998-06       Impact factor: 8.250

5.  Psychiatric disorders in patients with Fabry's disease.

Authors:  R P Grewal
Journal:  Int J Psychiatry Med       Date:  1993       Impact factor: 1.210

Review 6.  The adolescent with an inborn error of metabolism: medical issues and transition to adulthood.

Authors:  Gregory M Enns; Wendy Packman
Journal:  Adolesc Med       Date:  2002-06

7.  The impact of Gaucher disease and its treatment on quality of life.

Authors:  R P Hayes; K A Grinzaid; E B Duffey; L J Elsas
Journal:  Qual Life Res       Date:  1998-08       Impact factor: 4.147

Review 8.  Gaucher disease: recommendations on diagnosis, evaluation, and monitoring.

Authors:  J Charrow; J A Esplin; T J Gribble; P Kaplan; E H Kolodny; G M Pastores; C R Scott; R S Wappner; N J Weinreb; J S Wisch
Journal:  Arch Intern Med       Date:  1998-09-14

9.  Replacement therapy for inherited enzyme deficiency--macrophage-targeted glucocerebrosidase for Gaucher's disease.

Authors:  N W Barton; R O Brady; J M Dambrosia; A M Di Bisceglie; S H Doppelt; S C Hill; H J Mankin; G J Murray; R I Parker; C E Argoff
Journal:  N Engl J Med       Date:  1991-05-23       Impact factor: 91.245

10.  Psychological characteristics of breast cancer patients.

Authors:  B D Kirkcaldy; E Kobylinska
Journal:  Psychother Psychosom       Date:  1987       Impact factor: 17.659

View more
  8 in total

1.  Psychiatric and cognitive profile in Anderson-Fabry patients: a preliminary study.

Authors:  Perri Segal; Yoav Kohn; Yehuda Pollak; Gheona Altarescu; Esti Galili-Weisstub; Annick Raas-Rothschild
Journal:  J Inherit Metab Dis       Date:  2010-06-15       Impact factor: 4.982

2.  Psychological health in adults with morquio syndrome.

Authors:  Nadia Ali; S Cagle
Journal:  JIMD Rep       Date:  2015-01-23

3.  Young adults with MSUD and their transition to adulthood: psychosocial issues.

Authors:  Wendy Packman; Indira Mehta; Samantha Rafie; Jayanthi Mehta; Mariana Naldi; Kim Hart Mooney
Journal:  J Genet Couns       Date:  2012-02-17       Impact factor: 2.537

4.  Psychological aspects of patients with Fabry disease.

Authors:  T Wilson Crosbie; Wendy Packman; S Packman
Journal:  J Inherit Metab Dis       Date:  2009-10-31       Impact factor: 4.982

5.  Psychosocial issues in families affected by maple syrup urine disease.

Authors:  Wendy Packman; Shelly L Henderson; Indira Mehta; Rama Ronen; Dean Danner; Beth Chesterman; Seymour Packman
Journal:  J Genet Couns       Date:  2007-08-17       Impact factor: 2.537

Review 6.  Left to themselves: Time to target chronic pain in childhood rare diseases.

Authors:  Christine B Sieberg; Alyssa Lebel; Erin Silliman; Scott Holmes; David Borsook; Igor Elman
Journal:  Neurosci Biobehav Rev       Date:  2021-03-24       Impact factor: 8.989

7.  Evolution of prodromal clinical markers of Parkinson disease in a GBA mutation-positive cohort.

Authors:  Michelle Beavan; Alisdair McNeill; Christos Proukakis; Derralynn A Hughes; Atul Mehta; Anthony H V Schapira
Journal:  JAMA Neurol       Date:  2015-02       Impact factor: 18.302

8.  Health-related quality of life in children and adolescents living with Gaucher disease and their parents.

Authors:  Eduardo Remor; Antonio Baldellou
Journal:  Health Psychol Behav Med       Date:  2018-04-12
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.